quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:43:02·218d
PRRelease
Eagle Pharmaceuticals Inc. logo

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years

EGRX· Eagle Pharmaceuticals Inc.
Health Care
Original source

Companies

  • EGRX
    Eagle Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Aug 10UpdatePiper Sandler$17.00
  • Aug 9UpdatePiper Sandler$17.00

Related

  • PR99d
    Eagle Pharmaceuticals Announces Divestiture of Barhemsys
  • PR176d
    Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
  • PR184d
    Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders
  • PR190d
    Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements
  • PR199d
    Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
  • PR238d
    Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors
  • PR248d
    Eagle Pharmaceuticals Announces 2025 Annual Meeting Date
  • PR388d
    Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022